Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BYK 321084

Next Previous
X
Search
Drug Profile

BYK 321084

Alternative Names: BYK321084; PDE4 inhibitor - Nycomed; PDE4 inhibitor – Takeda; PDE4i – Nycomed; TAK-084; Type 4 cyclic nucleotide phosphodiesterase inhibitor – Nycomed

Latest Information Update: 29 Apr 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nycomed
  • Developer Takeda Pharmaceuticals International GmbH
  • Class Anti-inflammatories; Antipsoriatics; Phenanthridines; Skin disorder therapies
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Inflammation; Plaque psoriasis

Most Recent Events

  • 29 Apr 2016 No recent reports on development identified - Phase-I for Inflammation in Europe (Topical)
  • 29 Apr 2016 No recent reports on development identified - Phase-I for Plaque psoriasis in Germany (Topical)
  • 29 Apr 2016 Primary efficacy data from a phase I trial in Plaque psoriasis released by Takeda

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top